Hormonal Shifts Across Decades: Adapting Your Protocol
Male and female hormonal ageing follow different shapes, gradual in one case and a discrete transition in the other, and a protocol that ignores the difference will be wrong for one of them.
The Short Answer
The two sexes age hormonally in different shapes, and this is the fact that most general hormone advice fails to accommodate. Male testosterone declines gradually from around the third decade at roughly one per cent per year, with wide individual variation and a large contribution from health status rather than age. Female reproductive hormones fall through a discrete transition compressed into a few years. A gradual decline and a step change call for different monitoring intervals and different interventions.
Twenties and Thirties: Both Sexes
This is the period where the trajectory is set rather than managed, and the main hormonal risks are self-inflicted.
What matters: establishing sleep regularity, body composition and training habits, since all three determine hormonal status for decades. Avoiding the pattern of high training volume with deliberate restriction, which suppresses the axis in both sexes and reduces bone density during the window when peak bone mass is being set.
Women: cycle regularity is a useful health signal in its own right. Absent or irregular periods in the presence of adequate energy intake warrant assessment, and PCOS commonly presents in this period. Peak bone mass is reached in the twenties, and anything suppressing oestrogen here has permanent consequences.
Men: testosterone is near its peak, and the common causes of low levels at this age are obesity, sleep-disordered breathing, energy deficit with high training load, opioid or glucocorticoid use, and anabolic steroid use with subsequent suppression.
What does not matter: hormone-boosting supplements, in the absence of a demonstrated problem. There is nothing to boost in a healthy 30-year-old with adequate sleep and body composition.
Forties: Divergence Begins
Women. Perimenopause typically begins in the forties and can start earlier. Cycles become variable in length, oestradiol fluctuates unpredictably rather than simply declining, and symptoms often precede any change in cycle regularity. Vasomotor symptoms, sleep disruption, mood changes and cognitive complaints are common and are frequently attributed to stress or ageing rather than recognised.
The clinically important point: perimenopause is identified on symptoms and cycle pattern rather than on a blood test, because the fluctuation makes single values uninformative. A normal FSH does not exclude it.
Men. Gradual decline continues, and this is the decade where visceral adiposity and metabolic drift begin contributing substantially. In most men with low testosterone in this decade, the cause is health status rather than age, which means it is addressable.
Both. Thyroid dysfunction prevalence rises, and it is more common in women. Bone density begins declining, faster in women through the transition.
Monitoring shifts here. Women benefit from tracking symptoms and cycle pattern rather than repeated hormone panels; men benefit from a baseline morning testosterone with SHBG alongside metabolic markers.
Fifties: The Transition and Its Aftermath
| Change | Consequence | Priority |
|---|---|---|
| Menopause, average around 51 | Oestrogen falls to low levels durably | Bone, cardiovascular and symptom management |
| Accelerated bone loss | Fastest in the years around the final period | Resistance and impact loading, calcium and vitamin D adequacy, DEXA |
| Body composition shift | Fat redistribution toward visceral, lean mass loss | Resistance training and protein intake |
| Cardiovascular risk rises in women | Lipid profile worsens post-transition | ApoB and blood pressure become priorities |
| Continued male decline | Symptoms may emerge where levels were previously adequate | Confirm on repeat morning draw; address health status first |
| Sleep architecture changes both sexes | Fragmentation; sleep-disordered breathing prevalence rises | Assessment rather than sedation |
Hormone therapy deserves a plain statement here. For women with bothersome vasomotor symptoms, current guideline positions support hormone therapy as effective, with the risk profile depending on age, time since menopause, formulation and route. The historical over-reaction to early trial reporting led to a period in which many women were not offered an option that was appropriate for them, and current guidance is more nuanced than that legacy suggests. This is a clinical conversation, and it is one worth having rather than defaulting to supplements.
The same applies to testosterone therapy in men with confirmed symptomatic deficits: an appropriate clinical option with real considerations including fertility, haematocrit and prostate monitoring, and not something to approach through supplementation.
Sixties and Beyond
The hormonal picture is more stable post-transition, and the priorities shift to consequences rather than to the hormones themselves.
Bone. Fracture risk becomes a dominant concern, and a hip fracture in these decades carries mortality risk comparable to serious disease. Resistance and impact loading, adequate protein, calcium and vitamin D, and DEXA-guided assessment are the substance of it.
Muscle. Sarcopenia accelerates, and it predicts function, independence and mortality. Protein intake at 1.2 to 1.6 g per kg and resistance training are the interventions with real evidence.
Thyroid. Subclinical hypothyroidism becomes common, and the threshold for intervening in older adults is higher than in younger ones, since overtreatment carries atrial fibrillation and bone risks.
Medication load. Rises, and several classes affect hormone status or nutrient absorption. This becomes a routine review item.
What to stop doing: chasing youthful hormone levels as a target. The evidence for benefit is weakest in this direction, and the risks of intervention are highest here.
Monitoring Intervals by Decade
Twenties and thirties. No routine hormone testing without symptoms. Women: note cycle regularity. Both: a metabolic baseline is more useful than a hormone panel.
Forties. Men: baseline morning testosterone with SHBG, plus thyroid function, once. Women: symptom and cycle tracking; testing mainly to exclude other causes. Both: thyroid function, vitamin D, ferritin.
Fifties. Women: clinical review of transition symptoms and a bone density assessment, with cardiovascular markers becoming a priority. Men: repeat testosterone if symptomatic, with metabolic markers. Both: annual review.
Sixties onward. Thyroid function periodically, bone density on the interval your clinician advises, and medication review annually. Routine sex hormone monitoring is not generally indicated unless on replacement therapy.
The general principle is that testing frequency should follow the rate of change, and that the useful monitoring shifts from hormones themselves toward their consequences, bone, muscle, metabolic and cardiovascular markers, as the decades pass.
What Should Change and What Should Not
Across all decades, four things do not change: sleep regularity, resistance training, adequate protein and avoiding excess adiposity all support hormonal status at every age, in both sexes. A protocol built on those is never wrong.
What changes is everything else. The dominant threat moves from suppression by lifestyle in early adulthood, to metabolic drift in midlife, to the consequences of low oestrogen or testosterone in later decades. Interventions that are appropriate at one stage can be inappropriate at another: energy restriction that improves metabolic markers at 40 threatens bone and muscle at 70, and a supplement that supports an axis under stress is pointless in an axis that has completed a transition.
This is the case for reviewing rather than maintaining. A hormonal protocol assembled at 42 and unchanged at 55 has almost certainly outlived the situation it was built for, and a woman's has changed more than a man's over that interval.
The AEONNN Perspective
Pillar 2 is where AEONNN's Population layer does the heaviest lifting, because sex and life stage change the recommendation more here than anywhere else. A single hormone protocol applied across sexes and decades would be wrong for most of the people receiving it, which is the clearest possible argument for personalisation over a general stack.
The Contingency and continuity logic follows the different shapes of decline. A gradual male trajectory suits periodic measurement against a personal baseline. A compressed female transition suits symptom tracking, since fluctuation makes single values uninformative, and the platform reads the pattern rather than a number.
Two boundaries are stated plainly. Hormone therapy for bothersome menopausal symptoms is an effective clinical option under current guidance, and a wellness platform's role is to encourage that conversation rather than to substitute supplements for it. And chasing youthful hormone levels in later decades is where evidence for benefit is weakest and intervention risk is highest, so the platform's emphasis shifts to consequences, Pillar 7 bone and muscle, Pillar 4 cardiovascular markers, rather than to the hormones themselves.
Pillar Matrix mapping
Hormonal Optimization and Vitality, Longevity and Biological Age
Database Matrix layers
- Population Layer (UK Biobank, NHANES)
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
- Real-Time User Layer (wearable and adherence signals)
Frequently Asked
How does testosterone change with age?
Gradually, from around the third decade at roughly one per cent per year, with wide individual variation. In midlife, health status, particularly adiposity and sleep, contributes more than age in most men.
When does perimenopause start?
Typically in the forties, sometimes earlier. Symptoms often precede any change in cycle regularity, and oestradiol fluctuates unpredictably rather than simply declining.
Can a blood test confirm perimenopause in women?
No. Fluctuation makes single values uninformative, and a normal FSH does not exclude it. It is identified clinically on symptoms and cycle pattern.
What matters most after menopause?
Bone density and muscle mass, since accelerated bone loss occurs around the final period and fracture risk becomes a dominant concern. Cardiovascular markers also become a priority as the lipid profile shifts.
Is hormone therapy appropriate?
For women with bothersome vasomotor symptoms, current guideline positions support it as effective, with risk depending on age, time since menopause, formulation and route. It is a clinical conversation worth having.
Should older adults aim for youthful hormone levels?
The evidence for benefit is weakest in that direction and the risks of intervention are highest. Monitoring usefully shifts toward consequences: bone, muscle, metabolic and cardiovascular markers.
What supports hormonal health at every age?
Sleep regularity, resistance training, adequate protein and avoiding excess adiposity. These do not change across decades, and a protocol built on them is never wrong.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.